It has been well documented that systemic administration of ghrelin or endogenous ghrelin could restrict glucose-induced insulin release and deteriorate glucose tolerance in vivo and in vivo [34,35,36], which leads to insulin resistance, indirectly take part in obesity. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.